Chemical Diversity Labs, Sienabiotech S.p.A. Enter Research Collaboration

04-Dec-2003

Chemical Diversity Labs, Inc. (CDL), a leading provider of discovery chemistry services, and Sienabiotech S.p.A. of Siena, Italy, an integrated drug discovery company focused on disorders of the central nervous system, announced today that they have entered into an innovative research collaboration for evaluation and screening of a focused library. Under the terms of the agreement, Sienabiotech will use its methods and technology to screen the aspartyl protease focused library provided by CDL. To create the library, CDL applied its knowledge driven methods of focused library design, and additionally performed diversity optimization. Financial details were not disclosed. "Through this collaboration we expect to enhance the efficiency of our integrated drug discovery process which employs state-of-the-art platform technologies," said Georg C. Terstappen, V.P. Discovery Research of Sienabiotech. "Using Chemical Diversity Labs' compound collection and predictive technologies used to focus these libraries, we believe we can increase the chances of identifying high-quality leads. Moreover, the methods of diversity optimization allow us to acquire a diverse focused library set which takes into account the maximum feasible chemistry space." "Protease targeted libraries are notoriously difficult to develop, and we are proud that Sienabiotech values our in silico focusing methods," said Ilya Okun, Vice President of Research & Development at Chemical Diversity Labs. "We look forward to developing our research collaboration with Sienabiotech further, and will offer every support for all stages of the project we are partnering for".

https://www.chemeurope.com/en/news/32372/chemical-diversity-labs-sienabiotech-s-p-a-enter-research-collaboration.html